{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:00:41Z","timestamp":1790060441355,"version":"4.0.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Japanese Society for Inflammatory Bowel Disease"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>Acute severe ulcerative colitis (ASUC) refractory to intravenous corticosteroids (IVCS) is a major clinical challenge with limited rescue therapy options. Although tacrolimus has been proposed as a potential rescue therapy, its effectiveness and safety compared with infliximab, widely used in this setting, remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicenter retrospective cohort study was conducted across 34 Japanese institutions, including hospitalized patients with IVCS-refractory ASUC who received infliximab or tacrolimus as rescue therapy between January 2014 and March 2023. The primary outcome was clinical remission at day 14, using two-item patient-reported outcome scoring. Secondary outcomes included clinical response at day 3 and 7, colectomy, and adverse events within 56\u2009days. A modified Poisson regression model was used for analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 300 patients (infliximab, n\u2009=\u2009113; tacrolimus, n\u2009=\u2009187), clinical remission at day 14 occurred in 41.6% and 33.7%, respectively, with no difference (adjusted risk ratio [RR] 0.87 [95% CI: 0.65, 1.17]). Clinical response at day 3 was lower with tacrolimus (infliximab 42.5% vs tacrolimus 24.1%; adjusted RR 0.58 [95% CI: 0.42, 0.80]) but did not differ at day 7 (infliximab 63.7% vs tacrolimus 51.9%; adjusted RR 0.83 [95% CI: 0.69, 1.01]). No difference in colectomy within 56\u2009days was observed, although rates were higher in the tacrolimus (13.3% vs 20.3%; adjusted RR 1.58 [95% CI: 0.93, 2.67]). Adverse events were similar between groups (infliximab 8.8% vs tacrolimus 7.5%; adjusted RR 0.77 [95% CI: 0.37, 1.57]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tacrolimus demonstrated comparable effectiveness and safety to infliximab as rescue therapy for IVCS-refractory ASUC, although early response was slower.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag143","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T11:20:52Z","timestamp":1788693652000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of tacrolimus versus infliximab as rescue therapy for intravenous corticosteroid-refractory acute severe ulcerative colitis: a multicenter cohort study"],"prefix":"10.1093","volume":"20","author":[{"given":"Takahito","family":"Katano","sequence":"first","affiliation":[{"name":"Kajinoki Medical Clinic , Kani, Gifu,","place":["Japan"]},{"name":"Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences , Nagoya,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2683-9018","authenticated-orcid":false,"given":"Shinji","family":"Okabayashi","sequence":"additional","affiliation":[{"name":"Department of Healthcare Epidemiology, Graduate School of Medicine, Kyoto University , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Section of Clinical Epidemiology, Department of Community Medicine, Graduate School of Medicine, Kyoto University , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9750-8841","authenticated-orcid":false,"given":"Mao","family":"Matsubayashi","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Yokohama City University Medical Center , Yokohama, Kanagawa,","place":["Japan"]},{"name":"Department of Gastroenterology, Kitasato University Kitasato Institute Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanade","family":"Serizawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kitasato University Kitasato Institute Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kumamoto University , Kumamoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoki","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine , Isehara, Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center , Sakura, Chiba,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Ogihara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kyorin University School of Medicine , Mitaka, Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6315-3782","authenticated-orcid":false,"given":"Hiroki","family":"Kiyohara","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Tominaga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dokkyo Medical University School of Medicine , Tochigi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kaku","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, School of Medicine, Hyogo Medical University , Nishinomiya, Hyogo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayo","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Digestive Diseases Center, Showa Medical University Koto Toyosu Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3500-5488","authenticated-orcid":false,"given":"Katsuyoshi","family":"Ando","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University , Asahikawa, Hokkaido,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-0066","authenticated-orcid":false,"given":"Kousaku","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University Faculty of Medicine , Izumo, Shimane,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Shiraki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tohoku Rosai Hospital , Aobaku, Sendai,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruriko","family":"Nishigaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences , Nagoya,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Aizawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University Aizu Medical Center , Fukushima,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Kanazawa University Hospital , Kanazawa, Ishikawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Nishimata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sameshima Hospital , Kagoshima,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misaki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine , Tsu, Mie,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Takao","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Wakayama Medical University , Wakayama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Shimodate","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Center for Inflammatory Bowel Disease, Kurashiki Central Hospital , Kurashiki, Okayama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hakodate Municipal Hospital , Hakodate,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4779-9708","authenticated-orcid":false,"given":"Tsunaki","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine , Nagoya,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma","family":"Hotta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kyoto Second Red Cross Hospital , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Inokuchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ibuka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gifu University Graduate School of Medicine , Gifu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toranomon Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Medical University School of Medicine , Nagakute, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagoya City University East Medical Center , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiro","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Shinshu University School of Medicine , Matsumoto, Nagano,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kakimoto","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University , Takatsuki City, Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Yamagata University , Yamagata,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Mizoshita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyokawa City Hospital , Toyokawa, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakase","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Honzawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, The Third Department of Internal Medicine, Kansai Medical University , Hirakata, Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"IBD Terakoya Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2026092202070066100_jjag143-B1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"2026092202070066100_jjag143-B2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.cgh.2017.06.016","article-title":"Natural history of adult ulcerative colitis in population-based cohorts: a systematic review","volume":"16","author":"Fumery","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026092202070066100_jjag143-B3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/gutjnl-2022-327533","article-title":"Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response","volume":"72","author":"Adams","year":"2023","journal-title":"Gut"},{"key":"2026092202070066100_jjag143-B4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.dld.2008.03.014","article-title":"Colectomy rate in acute severe ulcerative colitis in the infliximab era","volume":"40","author":"Aratari","year":"2008","journal-title":"Dig Liver Dis"},{"key":"2026092202070066100_jjag143-B5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","article-title":"The pattern and outcome of acute severe colitis","volume":"4","author":"Dinesen","year":"2010","journal-title":"J Crohns Colitis"},{"key":"2026092202070066100_jjag143-B6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1177\/2050640620977405","article-title":"Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: a multicentre cohort study","volume":"9","author":"Festa","year":"2021","journal-title":"United Eur Gastroenterol J"},{"key":"2026092202070066100_jjag143-B7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third european evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026092202070066100_jjag143-B8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ecco-jcc\/jjab177","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment","volume":"16","author":"Spinelli","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026092202070066100_jjag143-B9","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","article-title":"Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review","volume":"17","author":"Gisbert","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026092202070066100_jjag143-B10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026092202070066100_jjag143-B11","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet"},{"key":"2026092202070066100_jjag143-B12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026092202070066100_jjag143-B13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.cgh.2020.03.072","article-title":"Baseline clearance of infliximab is associated with requirement for colectomy in patients with acute severe ulcerative colitis","volume":"19","author":"Battat","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026092202070066100_jjag143-B14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology"},{"key":"2026092202070066100_jjag143-B15","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2026092202070066100_jjag143-B16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10620-020-06177-7","article-title":"Hypoalbuminemia and bandemia predict failure of infliximab rescue therapy in acute severe ulcerative colitis","volume":"66","author":"Syal","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2026092202070066100_jjag143-B17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/gutjnl-2014-308099","article-title":"The association of tissue anti-tnf drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the atlas study","volume":"65","author":"Yarur","year":"2016","journal-title":"Gut"},{"key":"2026092202070066100_jjag143-B18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ibd.21853","article-title":"Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis","volume":"18","author":"Ogata","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2026092202070066100_jjag143-B19","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/gut.2005.081794","article-title":"A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis","volume":"55","author":"Ogata","year":"2006","journal-title":"Gut"},{"key":"2026092202070066100_jjag143-B20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J Gastroenterol"},{"key":"2026092202070066100_jjag143-B21","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third european evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026092202070066100_jjag143-B22","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"key":"2026092202070066100_jjag143-B23","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S2468-1253(24)00200-0","article-title":"Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial","volume":"9","author":"Choy","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026092202070066100_jjag143-B24","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/apt.13408","article-title":"Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials","volume":"42","author":"Jairath","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2026092202070066100_jjag143-B25","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"2026092202070066100_jjag143-B26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2026092202070066100_jjag143-B27","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"2026092202070066100_jjag143-B28","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jama.2020.12698","article-title":"Estimating risk ratios and risk differences: alternatives to odds ratios","volume":"324","author":"Holmberg","year":"2020","journal-title":"JAMA"},{"key":"2026092202070066100_jjag143-B29","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","article-title":"What\u2019s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes","volume":"280","author":"Zhang","year":"1998","journal-title":"JAMA"},{"key":"2026092202070066100_jjag143-B30","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1197\/j.aem.2006.11.038","article-title":"Advanced statistics: missing data in clinical research\u2014part 2: multiple imputation","volume":"14","author":"Newgard","year":"2007","journal-title":"Acad Emerg Med"},{"key":"2026092202070066100_jjag143-B31","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/ecco-jcc\/jjv221","article-title":"Efficacy and safety of tacrolimus therapy for active ulcerative colitis; a systematic review and meta-analysis","volume":"10","author":"Komaki","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2026092202070066100_jjag143-B32","doi-asserted-by":"publisher","first-page":"3162595","DOI":"10.1155\/2016\/3162595","article-title":"A comparison of short- and long-term therapeutic outcomes of infliximab- versus tacrolimus-based strategies for steroid-refractory ulcerative colitis","volume":"2016","author":"Endo","year":"2016","journal-title":"Gastroenterol Res Pract"},{"key":"2026092202070066100_jjag143-B33","doi-asserted-by":"publisher","first-page":"12546","DOI":"10.1038\/s41598-020-68828-z","article-title":"Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naive steroid-refractory ulcerative colitis patients","volume":"10","author":"Kitayama","year":"2020","journal-title":"Sci Rep"},{"key":"2026092202070066100_jjag143-B34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/CEG.S143224","article-title":"Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study","volume":"10","author":"Matsumoto","year":"2017","journal-title":"Clin Exp Gastroenterol"},{"key":"2026092202070066100_jjag143-B35","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/apt.13531","article-title":"Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study","volume":"43","author":"Yamamoto","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2026092202070066100_jjag143-B36","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41598-024-77365-y","article-title":"Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matching","volume":"15","author":"Yoshihara","year":"2025","journal-title":"Sci Rep"},{"key":"2026092202070066100_jjag143-B37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4103\/sjg.sjg_145_21","article-title":"The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory uc patients: a meta-analysis","volume":"27","author":"Zhao","year":"2021","journal-title":"Saudi J Gastroenterol"},{"key":"2026092202070066100_jjag143-B38","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.cgh.2018.04.060\/","article-title":"Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease","volume":"17","author":"Christensen","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026092202070066100_jjag143-B39","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"Stride-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/9\/jjag143\/71300161\/jjag143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/9\/jjag143\/71300161\/jjag143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:07:07Z","timestamp":1790057227000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag143\/8826377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag143","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9]]},"article-number":"jjag143"}}